{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:52:17Z","timestamp":1789051937851,"version":"build-2803163510"},"reference-count":188,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and\/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices\/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and\/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.<\/jats:p>","DOI":"10.1093\/europace\/euy174","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T04:35:27Z","timestamp":1531542927000},"page":"192-193","source":"Crossref","is-referenced-by-count":234,"title":["2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)"],"prefix":"10.1093","volume":"21","author":[{"given":"Gregory Y H","family":"Lip","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham, UK"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Phillippe","family":"Collet","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Paris 6, ACTION Study Group (www.action-coeur.org), Institut de Cardiologie H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (APHP), INSERM UMRS, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haude","sequence":"additional","affiliation":[{"name":"St\u00e4dtische Kliniken Neuss Lukaskrankenhaus Gmbh Kardiologie, Nephrologie, Pneumologie, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Byrne","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum Muenchen, Munich, Germany"},{"name":"DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene H","family":"Chung","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Medicine, Cardiology, Electrophysiology, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Trousseau et Facult\u00e9 de M\u00e9decine\u2014Universit\u00e9 Fran\u00e7ois Rabelais, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Lau","sequence":"additional","affiliation":[{"name":"Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Lopez-Cabanillas","sequence":"additional","affiliation":[{"name":"Clinica Adventista Belgrano, Instituto Del Corazon, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[{"name":"Cardiology Department, Humanitas Research Hospital, Rozzano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Obel","sequence":"additional","affiliation":[{"name":"Milpark Hospital, Cardiology Unit, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Inselspital, Cardiology, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Potpara","sequence":"additional","affiliation":[{"name":"School of Medicine, Belgrade University, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Blomstr\u00f6m Lundqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Crijns","sequence":"additional","affiliation":[{"name":"Cardiology Department, Maastricht UMC+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[{"name":"University Heart Center Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Heidb\u00fcchel","sequence":"additional","affiliation":[{"name":"Antwerp University and University Hospital, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Stankovic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhani","family":"Airaksinen","sequence":"additional","affiliation":[{"name":"Turku University Hospital, Cardiology, Department of Internal Medicine, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien M","family":"Ten Berg","sequence":"additional","affiliation":[{"name":"St. Antonius Hospital, Cardiology Department, Nieuwegein, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Ferrarotto Hospital, Azienda Ospedaliero-Univ, Policlinico-Vittorio Emanuele, University of Catania, Cardiologia Department, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Senior Interventional Cardiologist, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Bueno","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro, Madrid, Spain"},{"name":"Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiria Hospital Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[{"name":"Oberarzt, Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universit\u00e4t (LMU), Campus Gro\u00dfhadern, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Catholic University School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsiung","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Taipei Medical University, Taipei, Ta\u00efwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazem","family":"Akoum","sequence":"additional","affiliation":[{"name":"Cardiology Department, University of Washington, Seattle, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J","family":"Lockwood","sequence":"additional","affiliation":[{"name":"OU Heart Rhythm Institute, OU Health Sciences Center, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Rafael","family":"Gomez Flores","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cardiologia I. Chavez, Electrofisiologia, Mexico, DF Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Jardine","sequence":"additional","affiliation":[{"name":"Linmed Hospital, Benoni, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,21]]},"reference":[{"key":"2026080923265101800_euy174-B1","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B2","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"2026080923265101800_euy174-B3","first-page":"213","article-title":"The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension","volume":"33","author":"Chiang","year":"2017","journal-title":"Acta Cardiol Sin"},{"key":"2026080923265101800_euy174-B4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B6","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","author":"Steffel","year":"2018","journal-title":"Europace"},{"key":"2026080923265101800_euy174-B7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026080923265101800_euy174-B8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2017.05.016","article-title":"Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: the Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry","volume":"190","author":"Proietti","year":"2017","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jcin.2017.02.028","article-title":"Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents","volume":"10","author":"Choi","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.carrev.2017.03.015","article-title":"Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: insights from the Warfarin and Coronary Stenting (War-Stent) Registry","volume":"18","author":"Rubboli","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"2026080923265101800_euy174-B11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/1074248417698042","article-title":"Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel","volume":"22","author":"Verlinden","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026080923265101800_euy174-B12","first-page":"E64","article-title":"Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions","volume":"89","author":"Faza","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B13","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ejim.2016.08.022","article-title":"Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low-moderate risk of stroke?","volume":"35","author":"Fauchier","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2026080923265101800_euy174-B14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ahj.2016.07.015","article-title":"Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: insights from the Canadian observational AntiPlatelet sTudy","volume":"180","author":"Sra","year":"2016","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B15","first-page":"303","article-title":"Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention\u2014real life assessment","volume":"4","author":"Bogacki","year":"2016","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"2026080923265101800_euy174-B16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/clc.22486","article-title":"Ticagrelor in triple antithrombotic therapy: predictors of ischemic and bleeding complications","volume":"39","author":"Fu","year":"2016","journal-title":"Clin Cardiol"},{"key":"2026080923265101800_euy174-B17","doi-asserted-by":"crossref","first-page":"e0147245.","DOI":"10.1371\/journal.pone.0147245","article-title":"Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"11","author":"Sambola","year":"2016","journal-title":"PLoS One"},{"key":"2026080923265101800_euy174-B18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes","year":"2016","journal-title":"Am J Med"},{"key":"2026080923265101800_euy174-B19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.14740\/jocmr2443w","article-title":"Clinical relevance of anticoagulation and dual antiplatelet therapy to the outcomes of patients with atrial fibrillation and recent percutaneous coronary intervention with stent","volume":"8","author":"De Vecchis","year":"2016","journal-title":"J Clin Med Res"},{"key":"2026080923265101800_euy174-B20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jcin.2016.04.027","article-title":"Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention","volume":"9","author":"Koskinas","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B21","doi-asserted-by":"crossref","first-page":"e004310","DOI":"10.1161\/JAHA.116.004310","article-title":"Use of chronic oral anticoagulation and associated outcomes among patients undergoing percutaneous coronary intervention","volume":"5","author":"Secemsky","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026080923265101800_euy174-B22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","article-title":"Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification","volume":"80","author":"Sambola","year":"2016","journal-title":"Circ J"},{"key":"2026080923265101800_euy174-B23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","article-title":"Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome","volume":"135","author":"Braun","year":"2015","journal-title":"Thromb Res"},{"key":"2026080923265101800_euy174-B24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","article-title":"Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR Registry)","volume":"116","author":"Mennuni","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B26","doi-asserted-by":"crossref","first-page":"e0140101.","DOI":"10.1371\/journal.pone.0140101","article-title":"Triple antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with indication for oral anticoagulation: data from a single center registry","volume":"10","author":"Staudacher","year":"2015","journal-title":"PLoS One"},{"key":"2026080923265101800_euy174-B27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jjcc.2014.08.013","article-title":"Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting","volume":"65","author":"Kawai","year":"2015","journal-title":"J Cardiol"},{"key":"2026080923265101800_euy174-B28","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study","volume":"8","author":"Jackson","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B29","first-page":"264","article-title":"Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients","volume":"101","author":"Karrowni","year":"2015","journal-title":"Heart (British Cardiac Society)"},{"key":"2026080923265101800_euy174-B30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12928-013-0234-4","article-title":"Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents","volume":"29","author":"Enomoto","year":"2014","journal-title":"Cardiovasc Interv Ther"},{"key":"2026080923265101800_euy174-B31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"key":"2026080923265101800_euy174-B32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2014.03.060","article-title":"Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"114","author":"Goto","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B33","first-page":"280","article-title":"Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry","volume":"2","author":"Alonso","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080923265101800_euy174-B34","first-page":"234","article-title":"Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?","volume":"3","author":"D\u0105browska","year":"2013","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"2026080923265101800_euy174-B35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2013.08.005","article-title":"Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy","volume":"166","author":"Fosbol","year":"2013","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-013-0592-z","article-title":"Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents","volume":"102","author":"Seivani","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2026080923265101800_euy174-B37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11239-012-0790-y","article-title":"Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study","volume":"35","author":"Denas","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"2026080923265101800_euy174-B38","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.ahj.2015.08.023","article-title":"Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry","volume":"170","author":"Chandrasekhar","year":"2015","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B39","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","article-title":"An open-Label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B46","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B47","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B48","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B50","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","article-title":"Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2013.12.020","article-title":"Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial","volume":"167","author":"Bonaca","year":"2014","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B54","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60 mg compared with 90 mg twice-daily in the PEGASUS-TIMI 54 study","volume":"67","author":"Storey","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B56","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B57","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.08.089","article-title":"Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention","volume":"223","author":"Kowalewski","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B59","first-page":"517","article-title":"ESC\/EACTS myocardial revascularization guidelines 2014","volume":"46","author":"Kolh","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B61","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B62","first-page":"961","article-title":"Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study","volume":"38","author":"Naber","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B63","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2016.10.009","article-title":"2-Year outcomes of high bleeding risk patients after polymer-free drug-coated stents","volume":"69","author":"Garot","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B64","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jcin.2017.05.033","article-title":"Safety and efficacy of polymer-free biolimus A9-coated versus bare-metal stents in orally anticoagulated patients: 2-year results of the LEADERS FREE oral anticoagulation substudy","volume":"10","author":"Carrie","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B66","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","article-title":"Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B67","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.4244\/EIJ20170912-01","article-title":"Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary","volume":"13","author":"Byrne","year":"2018","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.4244\/EIJ-D-17-00492","article-title":"Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials","volume":"13","author":"Cassese","year":"2018","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B69","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2013.03.029","article-title":"Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events","volume":"62","author":"Rodes-Cabau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B70","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B71","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B72","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis","volume":"370","author":"Adams","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B73","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/eurheartj\/eht381","article-title":"The German Aortic Valve Registry (GARY): in-hospital outcome","volume":"35","author":"Hamm","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B74","doi-asserted-by":"crossref","first-page":"334","DOI":"10.7326\/M16-0060","article-title":"Transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and meta-analysis","volume":"165","author":"Gargiulo","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026080923265101800_euy174-B75","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehw225","article-title":"Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials","volume":"37","author":"Siontis","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B76","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B77","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B78","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2012.01.001","article-title":"2012 ACCF\/AATS\/SCAI\/STS expert consensus document on transcatheter aortic valve replacement","volume":"59","author":"Holmes","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B79","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/eurheartj\/ehs109","article-title":"Guidelines on the management of valvular heart disease (version 2012)","volume":"33","author":"Vahanian","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B80","first-page":"520","article-title":"Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement","volume":"28","author":"Webb","year":"2012","journal-title":"Can J Cardiol"},{"key":"2026080923265101800_euy174-B81","doi-asserted-by":"crossref","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"key":"2026080923265101800_euy174-B82","doi-asserted-by":"crossref","first-page":"W92","DOI":"10.4244\/EIJV11SWA28","article-title":"Antithrombotic therapy in TAVI patients: changing concepts","volume":"11(Suppl W)","author":"Gargiulo","year":"2015","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B83","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.jacc.2015.10.003","article-title":"Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial","volume":"66","author":"Dangas","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B84","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1160\/TH14-10-0821","article-title":"Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI)","volume":"113","author":"Nijenhuis","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B85","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4244\/EIJV8I12A209","article-title":"The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4, 571 patients","volume":"8","author":"Di Mario","year":"2013","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B86","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa1114705","article-title":"Registry of transcatheter aortic-valve implantation in high-risk patients","volume":"366","author":"Gilard","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B87","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.4244\/EIJY15M11_12","article-title":"A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation","volume":"12","author":"Sannino","year":"2016","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B88","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial","volume":"10","author":"Rodes-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B89","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jcin.2017.05.005","article-title":"Antithrombotic therapy for prevention of cerebral thromboembolic events after transcatheter aortic valve replacement: evolving paradigms and ongoing directions","volume":"10","author":"Capodanno","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B91","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2015.11.008","article-title":"Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation","volume":"173","author":"Nijenhuis","year":"2016","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B92","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.jacc.2015.10.018","article-title":"Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II","volume":"66","author":"Feldman","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B93","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacc.2011.08.067","article-title":"Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study","volume":"59","author":"Whitlow","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2017.07.714","article-title":"Transcatheter mitral valve replacement for degenerated bioprosthetic valves and failed annuloplasty rings","volume":"70","author":"Yoon","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B95","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"2026080923265101800_euy174-B96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3949\/ccjm.82a.14117","article-title":"Left atrial appendage closure: an emerging option in atrial fibrillation when oral anticoagulants are not tolerated","volume":"82","author":"Peritz","year":"2015","journal-title":"Cleve Clin J Med"},{"key":"2026080923265101800_euy174-B97","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B99","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.hrthm.2017.10.007","article-title":"Percutaneous left atrial appendage closure is not ready for routine clinical use","volume":"15","author":"Mandrola","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026080923265101800_euy174-B100","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","article-title":"Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation","volume":"71","author":"Fauchier","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B101","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4244\/EIJ-D-17-00493","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical\/echocardiographic data from a global prospective observational study","volume":"13","author":"Landmesser","year":"2017","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B102","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"11","author":"Tzikas","year":"2016","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2013.02.089","article-title":"Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy","volume":"62","author":"Urena","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B104","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.hrthm.2016.01.022","article-title":"Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation","volume":"13","author":"Lakkireddy","year":"2016","journal-title":"Heart Rhythm"},{"key":"2026080923265101800_euy174-B105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B106","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjcard.2016.06.018","article-title":"Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting","volume":"118","author":"Fauchier","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B107","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2015.07.064","article-title":"Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy","volume":"199","author":"Capodanno","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B108","doi-asserted-by":"crossref","first-page":"e000250.","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026080923265101800_euy174-B109","doi-asserted-by":"crossref","first-page":"f2573.","DOI":"10.1136\/bmj.f2573","article-title":"Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study","volume":"346","author":"Hippisley-Cox","year":"2013","journal-title":"BMJ"},{"key":"2026080923265101800_euy174-B110","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B111","doi-asserted-by":"crossref","first-page":"e006490","DOI":"10.1161\/JAHA.117.006490","article-title":"Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-stroke and CHA2DS2-VASc scores","volume":"6","author":"Rivera-Caravaca","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026080923265101800_euy174-B112","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07853890.2017.1378429","article-title":"Enhancing the \u2032real world\u2032 prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers","volume":"50","author":"Roldan","year":"2018","journal-title":"Ann Med"},{"key":"2026080923265101800_euy174-B113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B114","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1055\/s-0038-1651482","article-title":"Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in asian patients with atrial fibrillation: a Nationwide Cohort Study","volume":"118","author":"Yoon","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026080923265101800_euy174-B116","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B117","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B118","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B119","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Roldan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B120","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B121","doi-asserted-by":"crossref","first-page":"31755.","DOI":"10.1038\/srep31755","article-title":"Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: the Beijing PLA Hospital Atrial Fibrillation Project","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"2026080923265101800_euy174-B122","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med"},{"key":"2026080923265101800_euy174-B123","doi-asserted-by":"crossref","first-page":"109703","DOI":"10.18632\/oncotarget.19858","article-title":"Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"2026080923265101800_euy174-B124","doi-asserted-by":"crossref","first-page":"12066.","DOI":"10.1038\/s41598-017-11683-2","article-title":"Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation","volume":"7","author":"Rivera-Caravaca","year":"2017","journal-title":"Sci Rep"},{"key":"2026080923265101800_euy174-B125","doi-asserted-by":"crossref","first-page":"24376.","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"key":"2026080923265101800_euy174-B126","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/joim.12702","article-title":"Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial","volume":"283","author":"Proietti","year":"2018","journal-title":"J Intern Med"},{"key":"2026080923265101800_euy174-B127","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u2032real world\u2032 patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B128","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B129","doi-asserted-by":"crossref","first-page":"574.e13","DOI":"10.1016\/j.amjmed.2017.11.046","article-title":"The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants","volume":"131","author":"Lip","year":"2017","journal-title":"Am J Med"},{"key":"2026080923265101800_euy174-B130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCINTERVENTIONS.112.968792","article-title":"Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?","volume":"5","author":"Ruiz-Nodar","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B131","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B132","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B133","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"2026080923265101800_euy174-B134","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/eurheartj\/ehr369","article-title":"SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial","volume":"32","author":"Girasis","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B135","doi-asserted-by":"crossref","first-page":"1091.","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"key":"2026080923265101800_euy174-B136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B137","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B138","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B139","first-page":"888","article-title":"A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"38","author":"Fanola","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2017.11.004","article-title":"Prediction of long-term net clinical outcomes using the TIMI-AF score: comparison with CHA2DS2-VASc and HAS-BLED","volume":"197","author":"Rivera-Caravaca","year":"2018","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B141","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.amjcard.2017.09.003","article-title":"Usefulness of the 2MACE score to predicts adverse cardiovascular events in patients with atrial fibrillation","volume":"120","author":"Rivera-Caravaca","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B142","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1253\/circj.CJ-17-1318","article-title":"Comparison of the 2MACE and TIMI-AF scores for composite clinical outcomes in anticoagulated atrial fibrillation patients","volume":"82","author":"Pastori","year":"2018","journal-title":"Circ J"},{"key":"2026080923265101800_euy174-B143","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B144","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"2026080923265101800_euy174-B145","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1160\/TH17-08-0555","article-title":"Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry","volume":"117","author":"Mazurek","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B146","doi-asserted-by":"crossref","first-page":"3.","DOI":"10.1186\/s12873-018-0155-8","article-title":"Management and outcomes of patients presenting with sepsis and septic shock to the emergency department during nursing handover: a retrospective cohort study","volume":"18","author":"Alsolamy","year":"2018","journal-title":"BMC Emerg Med"},{"key":"2026080923265101800_euy174-B147","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B148","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B149","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2015.01.056","article-title":"Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study","volume":"183","author":"Kiviniemi","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ahj.2014.06.016","article-title":"Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin","volume":"168","author":"Baker","year":"2014","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B151","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4244\/EIJV8I9A162","article-title":"A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients","volume":"8","author":"Vranckx","year":"2013","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B152","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B153","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1160\/TH09-04-0245","article-title":"Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?","volume":"102","author":"Lahtela","year":"2009","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B154","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.amjcard.2013.09.043","article-title":"Frequency of radial artery occlusion after transradial access in patients receiving warfarin therapy and undergoing coronary angiography","volume":"113","author":"Pancholy","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026080923265101800_euy174-B155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/heart.88.4.331","article-title":"Heparin dose during percutaneous coronary intervention: how low dare we go?","volume":"88","author":"Niccoli","year":"2002","journal-title":"Heart"},{"key":"2026080923265101800_euy174-B156","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-8703(98)70223-6","article-title":"How does warfarin affect the activated coagulation time?","volume":"136","author":"Chang","year":"1998","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B157","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"2026080923265101800_euy174-B158","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.thromres.2014.01.038","article-title":"Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy","volume":"133","author":"Kiviniemi","year":"2014","journal-title":"Thromb Res"},{"key":"2026080923265101800_euy174-B159","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","article-title":"Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B160","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","article-title":"Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention","volume":"111","author":"Hochholzer","year":"2005","journal-title":"Circulation"},{"key":"2026080923265101800_euy174-B161","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"key":"2026080923265101800_euy174-B162","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","article-title":"Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel","volume":"50","author":"Payne","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026080923265101800_euy174-B163","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.atherosclerosis.2009.03.011","article-title":"Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention\u2014effects on soluble CD40 ligand concentrations","volume":"206","author":"Dominguez-Rodriguez","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026080923265101800_euy174-B164","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080923265101800_euy174-B166","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"2026080923265101800_euy174-B167","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B168","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4244\/EIJY14M06_07","article-title":"Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial","volume":"11","author":"Dewilde","year":"2015","journal-title":"EuroIntervention"},{"key":"2026080923265101800_euy174-B169","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jcin.2016.03.038","article-title":"Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials","volume":"9","author":"Kang","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080923265101800_euy174-B170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B171","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B172","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/europace\/euu208","article-title":"Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force","volume":"16","author":"Gorenek","year":"2014","journal-title":"Europace"},{"key":"2026080923265101800_euy174-B173","article-title":"Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry","author":"Zeymer","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080923265101800_euy174-B174","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","article-title":"Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients","volume":"117","author":"Rivera-Caravaca","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B175","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2017.01.003","article-title":"New-onset atrial fibrillation after percutaneous coronary intervention with stent: updated proposal of an algorithm for the choice of oral anticoagulant and its dose","volume":"40","author":"Rubboli","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2026080923265101800_euy174-B176","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"2026080923265101800_euy174-B177","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","article-title":"Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease","volume":"64","author":"Hamon","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080923265101800_euy174-B178","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2017.10.091","article-title":"Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: an analysis from the SPORTIF trials","volume":"252","author":"Proietti","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026080923265101800_euy174-B179","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ahj.2006.06.003","article-title":". Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial","volume":"152","author":"Gibson","year":"2006","journal-title":"Am Heart J"},{"key":"2026080923265101800_euy174-B181","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1160\/TH17-02-0122","article-title":"On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel","volume":"117","author":"Bomicke","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B182","first-page":"844","article-title":"Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data","volume":"115","author":"Reny","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B183","doi-asserted-by":"crossref","first-page":"829.","DOI":"10.1160\/TH17-03-0167","article-title":"High on treatment platelet reactivity as a risk factor for adverse left ventricular remodelling after STEMI","volume":"117","author":"Podda","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B184","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1160\/TH16-12-0911","article-title":"Platelet receptors as therapeutic targets: past, present and future","volume":"117","author":"Jamasbi","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B185","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1160\/TH16-10-0807","article-title":"New developments in anticoagulants: past, present and future","volume":"117","author":"Weitz","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080923265101800_euy174-B186","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13543784.2018.1416090","article-title":"New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds","volume":"27","author":"Dimitropoulos","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2026080923265101800_euy174-B187","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 Scientific Sessions Sol sherry distinguished lecture in thrombosis: factor XI as a target for new anticoagulants","volume":"38","author":"Weitz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080923265101800_euy174-B188","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/21\/2\/192\/70576806\/europace_21_2_192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/21\/2\/192\/70576806\/europace_21_2_192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:38:57Z","timestamp":1786333137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/21\/2\/192\/5056658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,21]]},"references-count":188,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euy174","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,7,21]]}}}